Ann: Immutep presents positive TACTI-mel melanoma trial data, page-133

Originally posted by Len

Sorry, but I did say it's confusing. Resolution 8 is 1 for 10 consolidation = risk. Resolution 3 will dilute shares by 10%. Resolution 4 and 5 are for prior capital raises which diluted shares. And I don't hold IMM. Just watching. 12 month return is minus 37%! Do you think the constant dilution is good for the SP?

Hi Len

Statistically Bio tech is seldom good for traders and rarely good for investors or patients. When a treatment or drug does progress all the way to approved, investors can do very well and patients even better. Holders are effectively supporting the company research, when they take up share offerings. This is how the company survives long enough to progress drug trials through to commercialisation.
Dilution maybe. Investment in the potential of a cure is how I perceive it. DYOR. I’ve been involved in every capital raising offer for the past 10 years. I do this to assist the business to continue with R&D. If IMM commercialises a product, financially I will benefit and most importantly patients are cured. What investors get and traders get are two different things here. Work out what you are and set your own goals. One persons objectives and perception is Just that. There are other forces at play. Biotechs and the illnesses they are working on have a significant ethical aspect which should be considered in any appraisal. Good luck to you.